The tumor-bearing state induces augmented responses of organ-associated lymphocytes to high-dose interleukin-2 therapy in mice

Cancer Immunology Immunotherapy

Volumn 45, Issue 2, 1997, Pages 63-70

  Asano, Y ^a   Kaneda, K ^b   Hiragushi, J ^a   Tsuchida, T ^a   Higashino, K ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Interleukin 2; Liver; Lung; Organ associated lymphocytes; Tumor bearing state

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MYELOMA; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; FEMALE; FLOW CYTOMETRY; INTERLEUKIN-2; LYMPHOCYTES; MICE; MICE, INBRED C3H; MICROSCOPY, ELECTRON; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0030664356     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050403     Document Type: Article

References (26)

1. Abo T (1992) Extrathymic differentiation of T lymphocytes and its biological function. Biomed Res 13:1
2. Dubinett SM, Huang M, Lichtenstein A, Mcbride WH, Wang J, Markovitz G, Kelley D, Grody WW, Mintz LE, Dhanani S (1994) Tumor necrosis factor-α plays a central role in interleukin-2 induced pulmonary vascular leak and lymphocyte accumulation. Cell Immunol 157:170
3. Ettinghausen SE, Lipford III EH, Mulé JJ, Rosenberg SA (1985) Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 135:3623
4. Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80:177
5. Fujikura S, Watanabe H, Abo T, Kaneda K (1995) Ultrastructural comparison of CD3-intermediate positive T cells and natural killer cells from the liver of mice. In: Wisse E, Knook DL, Wake K (eds) Cells of the Hepatic Sinusoid, vol 5. Kupffer Cell Foundation, Rijswijk, pp 156
6. Goossens PL, Jouin H, Marchal G, Milon G (1990) Isolation and flow cytometric analysis of the free lymphomyeloid cells present in murine liver. J Immunol Methods 132:137
7. Kaneda K, Wake K (1990) Ultrastructural study of in vivo tumor cell lysis by liver-associated natural killer cells. Biomed Res 11:137
8. Kaneda K, Nagamuta M, Kataoka M, Yamamoto H, Kishiye T, Wake K (1991) Ultrastructural characteristics of lymphokine-activated killer cells of the rat in comparison with natural killer cells. Arch Histol Cytol 54:119
9. Lotze MT (1995) Biologic therapy with interleukin-2: preclinical studies. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, p 207
10. Mark SR, Michael PK, Caroline O, Jim K, Leslie W, Steven AC, Eva L (1992) Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. Clin Exp Metastasis 10:317
11. Rosenberg SA, Mule JJ, Spiess PJ (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169
12. Rosenberg SA, Lotze MT, Muul LM (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316:889
13. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) The treatment of 238 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin2. JAMA 271:907
14. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137:1735
15. Seki S, Abo T, Sugiura K, Ohleki T, Kobata T, Yagita H, Okumura K, Rikiishi H, Masuda T, Kumagai K (1991) Reciprocal T-cell responses in the liver and thymus of mice injected with syngenic tumor cells. Cell Immunol 137:46
16. Smith KA (1984) Interleukin-2. Annu Rev Immunol 2:319
17. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X, Shimizu J, Fujivvara H, Hamaoka T (1991) Transforming growth factor-β-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 146:1077
18. Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R (1987) Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47:5725
19. Tanaka T, Tsuda M, Karasuyama H, Kitamura F, Kono T, Hatakeyama M, Taniguchi T, Miyasaka M (1991) A novel monoclonal antibody against murine interleukin-2 receptor beta-chain; characterization of receptor expression in normal lymphoid cells and EL-4 cell. J Immunol 147:2222
20. Watanabe H, Ohtsuka K, Kimura M, Ikarashi Y, Ohmori K, Kusumi A, Ohteki T, Seki S, Abo T (1992) Details of an isolation method for hepatic lymphocytes in mice. J Immunol Methods 146:145
21. Watanabe H, Miyaji C, Kawachi Y, Iiai T, Ohtsuka K, Iwanaga T, Takahashi-Iwanaga H. Abo T (1995) Relationships between intermediate TCR cells and NK1.1+ T cells in various immune organs: NK1.1+ T cells are present within a population of intermediate TCR cells. J Immunol 155:2972
22. Wiltrout RH, Mathieson BJ, Tulmadge JE, Reynolds CW, Zhang S-R, Herberman RB, Ortaldo JR (1984) Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med 160:1431
23. Wiltrout RH, Herberman RB, Zhang S-R, Chirigos MA, Ortaldo JR, Green KM, Talmadge JE (1985) Role of organ-associated NK cells in decreased formation of experimental metastasis in lung and liver. J Immunol 134:4267
24. Wiltrout RH, Pilaro AM, Gruys ME, Talmadge JE, Longo DL, Ortaldo JR, Reynolds CW (1989) Augmentation of mouse liver-associated NK activity by biological response modifiers occurs largely via rapid recruitment of LGL from the bone marrow. J Immunol 143:372
25. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Etlinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI, Levin R, Guleria A, MacFarlane MP, White RL, Einhorn JH, Seipp CA, Rosenberg SA (1994) Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 12:1572
26. Zhang S-R, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB, Wiltrout RH (1986) Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 1. Cancer Immunol Immunother 21:19